Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)        
Revenues, net $ 8,817 $ 29,809 $ 34,659 $ 100,399
Operating expenses:        
Cost of implants and other costs 1,022 16,550 3,450 66,994
Research and development 589,985 1,289,366 1,371,484 3,344,970
Selling, general and administrative 892,232 757,582 2,638,051 2,355,670
Impairment of intellectual property 141,480 0 141,480 0
Depreciation and amortization 18,747 19,169 57,465 57,506
Total operating expenses 1,643,466 2,082,667 4,211,930 5,825,140
Loss from operations (1,634,649) (2,052,858) (4,177,271) (5,724,741)
Other income (expenses):        
Interest expense, net (141,140) (129,946) (391,297) (380,981)
Grant income 412,552 1,392,632 531,134 3,498,084
Other miscellaneous income 0 5,000 28,229 5,799
Total other income 271,412 1,267,686 168,066 3,122,902
Net loss before provision for income taxes (1,363,237) (785,172) (4,009,205) (2,601,839)
Income taxes 0   0 0
Net loss (1,363,237) (785,172) (4,009,205) (2,601,839)
Non-controlling interest 398 17,511 1,866 32,179
Net loss attributable to BioCorRx Inc. $ (1,362,839) $ (767,661) $ (4,007,339) $ (2,569,660)
Net loss per common share, basic and diluted $ (0.21) $ (0.14) $ (0.62) $ (0.48)
Weighted average number of common shares outstanding, basic and diluted 6,630,850 5,386,935 6,424,770 5,362,344